Hair Loss with Daratumumab is Not a Recognized Side Effect
Frontal hairline hair loss is not a documented or expected side effect of daratumumab (Darzalex) therapy for multiple myeloma. This symptom warrants investigation for alternative causes rather than attribution to the medication.
Evidence from FDA Drug Labeling and Clinical Trials
The FDA prescribing information for daratumumab does not list hair loss (alopecia) among its adverse reactions 111. The most common side effects documented include:
- Infusion-related reactions (predominantly during first infusion)
- Upper respiratory tract infections
- Fatigue
- Nausea
- Diarrhea
- Constipation
- Decreased blood cell counts (neutropenia, thrombocytopenia, anemia)
- Peripheral neuropathy (though this is more commonly associated with combination partners like bortezomib)
Clinical Trial Safety Data
Multiple large phase III trials evaluating daratumumab in various combinations have not reported hair loss as a significant adverse event:
CASTOR trial (daratumumab + bortezomib + dexamethasone): The most common toxicities were thrombocytopenia (54%) and peripheral neuropathy (47%), with infusion reactions being the primary daratumumab-specific concern 222
POLLUX trial (daratumumab + lenalidomide + dexamethasone): Increased neutropenia and thrombocytopenia were noted, along with upper respiratory tract infections, but no mention of alopecia 222
ALCYONE and MAIA trials (newly diagnosed patients): Similar safety profiles without documented hair loss 3
Alternative Explanations to Consider
1. Combination Therapy Partners
If this patient is receiving daratumumab in combination with other agents, consider:
- Cyclophosphamide: Known to cause alopecia
- Doxorubicin: Commonly causes hair loss
- High-dose corticosteroids: Can contribute to hair thinning
2. Disease-Related Factors
- Multiple myeloma itself can cause systemic effects including nutritional deficiencies
- Anemia (common in myeloma) can contribute to hair changes
- Renal dysfunction may affect hair health
3. Other Medical Conditions
- Thyroid dysfunction (hypothyroidism or hyperthyroidism)
- Nutritional deficiencies (iron, zinc, biotin, protein)
- Androgenetic alopecia (age-related pattern hair loss)
- Telogen effluvium from systemic stress
4. Interesting Contrast: Pomalidomide
Notably, there is a documented case of hair texture change (straight to curly) with pomalidomide use 4, demonstrating that immunomodulatory drugs can affect hair, but this is distinctly different from hair loss and involves a different agent.
Recommended Clinical Approach
Immediate steps:
- Review complete medication list including all combination partners with daratumumab
- Assess for cytopenias: Check CBC to evaluate for anemia or other deficiencies
- Evaluate thyroid function: TSH, free T4
- Nutritional assessment: Ferritin, iron studies, vitamin D, B12
- Examine scalp: Look for inflammatory conditions, scarring, or other dermatologic causes
Common pitfall: Attributing all new symptoms during cancer treatment to the newest or most prominent medication without systematic evaluation of other causes.
Clinical Context
The guidelines emphasize monitoring for hematologic toxicities (neutropenia, thrombocytopenia, anemia) with daratumumab 35, but hair loss is conspicuously absent from toxicity profiles across all major clinical practice guidelines 3367.
Bottom line: This patient's frontal hairline hair loss should prompt investigation for alternative etiologies rather than being dismissed as a daratumumab side effect. The extensive clinical trial experience with daratumumab, involving thousands of patients, has not identified alopecia as a treatment-related adverse event.